Cancers, Vol. 12, Pages 486: Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma

Cancers, Vol. 12, Pages 486: Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma Cancers doi: 10.3390/cancers12020486 Authors: Bastien Jamet Clément Bailly Thomas Carlier Cyrille Touzeau Anne-Victoire Michaud Mickael Bourgeois Philippe Moreau Caroline Bodet-Milin Françoise Kraeber-Bodere Multiple myeloma (MM) is always preceded by an initial monoclonal gammopathy of undetermined significance (MGUS) that then develops into asymptomatic or smoldering multiple myeloma (SMM), which constitutes an intermediate clinical stage between MGUS and MM. According to a recent study, risk factors for faster MGUS to MM progression include an M protein of 1.5 g/dL or more and an abnormal free light chain ratio in patients with non-IgM MGUS. Therefore, the International Myeloma Working Group (IMWG) decided to recommend whole-body computed tomography (WBCT) for patients with high-risk MGUS in order to exclude early bone destruction. Studies evaluating magnetic resonance imaging (MRI) in SMM found an optimal cutoff of two or more focal lesions to be of prognostic significance for fast progression into symptomatic disease and considered this biomarker as a myeloma-defining event (MDE) needing to start therapy with the aim to avoid progression to harmful bone lesions. Moreover, studies assessing positron emission tomography (PET) with computed tomography (CT) using 18F-deoxyglucose (FDG) (FDG-PET/CT) in SMM showed that presence of...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research